Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

Phase 1CompletedNCT00440427

Wyeth is now a wholly owned subsidiary of Pfizer12 enrolled

Overview

To assess the initial pharmacokinetic profile of single doses of 25mg and 50 mg of DVS SR to healthy subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

* Men or non-pregnant, non-lactating women * Body mass index 18 - 30 kg/m2 * Body weight greater than or equal to 60kg

Unnamed facility

Boston, Massachusetts, United States

Safety

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.